Back to Agenda
Session 3: Impact of Early Patient Engagement
Session Chair(s)
Steven L. Roberds, PhD
Chief Scientific Officer
Tuberous Sclerosis Alliance, United States
In this session we will address both the value of and the challenges in engaging patients early-on in the clinical development process. Experts will review the specific concepts and principles relating to overcoming barriers and demonstrate how patient engagement can be successfully interwoven in regulatory and clinical programs.
Speaker(s)
Addressing the Challenges of Early Patient Engagement
Tiffany House, JD
Acid Maltase Deficiency Association (AMDA), United States
President
Putting it All Together
Richard Klein
GE2P2 Global Foundation, United States
Director, Expanded Access Programs & Policy, Former FDA, Patient Liaison
Interactive Panel Discussion
Molly White
Myotonic Dystrophy Foundation, United States
Executive Director
Joel Beetsch, PhD
Celgene Corporation, United States
Vice President, Global Patient Advocacy
Tiffany House, JD
Acid Maltase Deficiency Association (AMDA), United States
President
Have an account?